Baidu
map

MedSci参加“第二届中国实效研究和循证医学高峰会议 (CORE SUMMIT)”

2012-04-01 MedSci MedSci原创

2012年3月31日,由中国医师协会和美国华斯泰生命策略研究所(VitalStrategic Research Institute)联合举办的【第二届中国实效研究和循证医学高峰会议】(简称CORE Summit)在上海国际会议中心落下帷幕。本次会议吸引到160多名国内外相关学者参加,就实效研究以及循证医学进行深入交流和讨论。实效研究和循证研究能够反映出地区乃至国家存在的卫生问题以及人群的卫生需求,

2012年3月31日,由中国医师协会和美国华斯泰生命策略研究所(VitalStrategic Research Institute)联合举办的【第二届中国实效研究和循证医学高峰会议】(简称CORE Summit)在上海国际会议中心落下帷幕。本次会议吸引到160多名国内外相关学者参加,就实效研究以及循证医学进行深入交流和讨论。
实效研究和循证研究能够反映出地区乃至国家存在的卫生问题以及人群的卫生需求,还能评价卫生保健服务措施的效果及经济和社会效益。本次会议为中外关心医疗实效研究的同行提供了一个很好的交流平台,得到了与会者很好的评价。会上,专家们回顾了实效研究的过去,也展望了实效研究的未来,同时就循证医学对企业策略、政府政策和临床实践的影响作出了详细的介绍。另外对医疗管理技术、电子医学和统计模型也进行了深刻的交流。
MedSci作为专业的科研和临床学术服务平台应邀参展,与众多专家学者就循证医学和临床科研成果的转化问题进行了深刻的讨论并获益匪浅。MedSci在临床科研教育培训中,一直积极地传播与分享“循证医学分析的研究过程、循证医学选题及分析方法、循证医学与临床争议问题解析”等主题内容,今后将继续重视实效研究和医学研究的科学性,为提高广大临床科研工作者的科研意识,提高科研水平,进一步促进临床科研成果的转化而努力。

会议现场

MedSci工作人员与专家合影

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1795196, encodeId=5ef21e95196d0, content=<a href='/topic/show?id=aeac1689e5b' target=_blank style='color:#2F92EE;'>#SUMMIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16897, encryptionId=aeac1689e5b, topicName=SUMMIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Wed Apr 25 00:47:00 CST 2012, time=2012-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900786, encodeId=22861900e8635, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Fri Oct 05 09:47:00 CST 2012, time=2012-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022439, encodeId=1e29202243935, content=<a href='/topic/show?id=53564603527' target=_blank style='color:#2F92EE;'>#实效研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46035, encryptionId=53564603527, topicName=实效研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f2c2500194, createdName=446798725_87912765, createdTime=Sat Aug 18 04:47:00 CST 2012, time=2012-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379429, encodeId=41a113e9429e6, content=<a href='/topic/show?id=4f12504e147' target=_blank style='color:#2F92EE;'>#循证医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50471, encryptionId=4f12504e147, topicName=循证医学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Tue Apr 03 08:47:00 CST 2012, time=2012-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449639, encodeId=9dff1449639c2, content=<a href='/topic/show?id=0bd850468be' target=_blank style='color:#2F92EE;'>#循证#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50468, encryptionId=0bd850468be, topicName=循证)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca95510093, createdName=xjy04, createdTime=Tue Apr 03 08:47:00 CST 2012, time=2012-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561978, encodeId=afc015619e89d, content=<a href='/topic/show?id=309f509e9a' target=_blank style='color:#2F92EE;'>#CORE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5097, encryptionId=309f509e9a, topicName=CORE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Apr 03 08:47:00 CST 2012, time=2012-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605670, encodeId=e4e116056e059, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Apr 03 08:47:00 CST 2012, time=2012-04-03, status=1, ipAttribution=)]
    2012-04-25 huirong
  2. [GetPortalCommentsPageByObjectIdResponse(id=1795196, encodeId=5ef21e95196d0, content=<a href='/topic/show?id=aeac1689e5b' target=_blank style='color:#2F92EE;'>#SUMMIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16897, encryptionId=aeac1689e5b, topicName=SUMMIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Wed Apr 25 00:47:00 CST 2012, time=2012-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900786, encodeId=22861900e8635, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Fri Oct 05 09:47:00 CST 2012, time=2012-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022439, encodeId=1e29202243935, content=<a href='/topic/show?id=53564603527' target=_blank style='color:#2F92EE;'>#实效研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46035, encryptionId=53564603527, topicName=实效研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f2c2500194, createdName=446798725_87912765, createdTime=Sat Aug 18 04:47:00 CST 2012, time=2012-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379429, encodeId=41a113e9429e6, content=<a href='/topic/show?id=4f12504e147' target=_blank style='color:#2F92EE;'>#循证医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50471, encryptionId=4f12504e147, topicName=循证医学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Tue Apr 03 08:47:00 CST 2012, time=2012-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449639, encodeId=9dff1449639c2, content=<a href='/topic/show?id=0bd850468be' target=_blank style='color:#2F92EE;'>#循证#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50468, encryptionId=0bd850468be, topicName=循证)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca95510093, createdName=xjy04, createdTime=Tue Apr 03 08:47:00 CST 2012, time=2012-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561978, encodeId=afc015619e89d, content=<a href='/topic/show?id=309f509e9a' target=_blank style='color:#2F92EE;'>#CORE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5097, encryptionId=309f509e9a, topicName=CORE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Apr 03 08:47:00 CST 2012, time=2012-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605670, encodeId=e4e116056e059, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Apr 03 08:47:00 CST 2012, time=2012-04-03, status=1, ipAttribution=)]
    2012-10-05 gracezdd
  3. [GetPortalCommentsPageByObjectIdResponse(id=1795196, encodeId=5ef21e95196d0, content=<a href='/topic/show?id=aeac1689e5b' target=_blank style='color:#2F92EE;'>#SUMMIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16897, encryptionId=aeac1689e5b, topicName=SUMMIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Wed Apr 25 00:47:00 CST 2012, time=2012-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900786, encodeId=22861900e8635, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Fri Oct 05 09:47:00 CST 2012, time=2012-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022439, encodeId=1e29202243935, content=<a href='/topic/show?id=53564603527' target=_blank style='color:#2F92EE;'>#实效研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46035, encryptionId=53564603527, topicName=实效研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f2c2500194, createdName=446798725_87912765, createdTime=Sat Aug 18 04:47:00 CST 2012, time=2012-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379429, encodeId=41a113e9429e6, content=<a href='/topic/show?id=4f12504e147' target=_blank style='color:#2F92EE;'>#循证医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50471, encryptionId=4f12504e147, topicName=循证医学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Tue Apr 03 08:47:00 CST 2012, time=2012-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449639, encodeId=9dff1449639c2, content=<a href='/topic/show?id=0bd850468be' target=_blank style='color:#2F92EE;'>#循证#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50468, encryptionId=0bd850468be, topicName=循证)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca95510093, createdName=xjy04, createdTime=Tue Apr 03 08:47:00 CST 2012, time=2012-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561978, encodeId=afc015619e89d, content=<a href='/topic/show?id=309f509e9a' target=_blank style='color:#2F92EE;'>#CORE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5097, encryptionId=309f509e9a, topicName=CORE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Apr 03 08:47:00 CST 2012, time=2012-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605670, encodeId=e4e116056e059, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Apr 03 08:47:00 CST 2012, time=2012-04-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1795196, encodeId=5ef21e95196d0, content=<a href='/topic/show?id=aeac1689e5b' target=_blank style='color:#2F92EE;'>#SUMMIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16897, encryptionId=aeac1689e5b, topicName=SUMMIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Wed Apr 25 00:47:00 CST 2012, time=2012-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900786, encodeId=22861900e8635, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Fri Oct 05 09:47:00 CST 2012, time=2012-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022439, encodeId=1e29202243935, content=<a href='/topic/show?id=53564603527' target=_blank style='color:#2F92EE;'>#实效研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46035, encryptionId=53564603527, topicName=实效研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f2c2500194, createdName=446798725_87912765, createdTime=Sat Aug 18 04:47:00 CST 2012, time=2012-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379429, encodeId=41a113e9429e6, content=<a href='/topic/show?id=4f12504e147' target=_blank style='color:#2F92EE;'>#循证医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50471, encryptionId=4f12504e147, topicName=循证医学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Tue Apr 03 08:47:00 CST 2012, time=2012-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449639, encodeId=9dff1449639c2, content=<a href='/topic/show?id=0bd850468be' target=_blank style='color:#2F92EE;'>#循证#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50468, encryptionId=0bd850468be, topicName=循证)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca95510093, createdName=xjy04, createdTime=Tue Apr 03 08:47:00 CST 2012, time=2012-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561978, encodeId=afc015619e89d, content=<a href='/topic/show?id=309f509e9a' target=_blank style='color:#2F92EE;'>#CORE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5097, encryptionId=309f509e9a, topicName=CORE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Apr 03 08:47:00 CST 2012, time=2012-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605670, encodeId=e4e116056e059, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Apr 03 08:47:00 CST 2012, time=2012-04-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1795196, encodeId=5ef21e95196d0, content=<a href='/topic/show?id=aeac1689e5b' target=_blank style='color:#2F92EE;'>#SUMMIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16897, encryptionId=aeac1689e5b, topicName=SUMMIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Wed Apr 25 00:47:00 CST 2012, time=2012-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900786, encodeId=22861900e8635, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Fri Oct 05 09:47:00 CST 2012, time=2012-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022439, encodeId=1e29202243935, content=<a href='/topic/show?id=53564603527' target=_blank style='color:#2F92EE;'>#实效研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46035, encryptionId=53564603527, topicName=实效研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f2c2500194, createdName=446798725_87912765, createdTime=Sat Aug 18 04:47:00 CST 2012, time=2012-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379429, encodeId=41a113e9429e6, content=<a href='/topic/show?id=4f12504e147' target=_blank style='color:#2F92EE;'>#循证医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50471, encryptionId=4f12504e147, topicName=循证医学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Tue Apr 03 08:47:00 CST 2012, time=2012-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449639, encodeId=9dff1449639c2, content=<a href='/topic/show?id=0bd850468be' target=_blank style='color:#2F92EE;'>#循证#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50468, encryptionId=0bd850468be, topicName=循证)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca95510093, createdName=xjy04, createdTime=Tue Apr 03 08:47:00 CST 2012, time=2012-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561978, encodeId=afc015619e89d, content=<a href='/topic/show?id=309f509e9a' target=_blank style='color:#2F92EE;'>#CORE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5097, encryptionId=309f509e9a, topicName=CORE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Apr 03 08:47:00 CST 2012, time=2012-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605670, encodeId=e4e116056e059, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Apr 03 08:47:00 CST 2012, time=2012-04-03, status=1, ipAttribution=)]
    2012-04-03 xjy04
  6. [GetPortalCommentsPageByObjectIdResponse(id=1795196, encodeId=5ef21e95196d0, content=<a href='/topic/show?id=aeac1689e5b' target=_blank style='color:#2F92EE;'>#SUMMIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16897, encryptionId=aeac1689e5b, topicName=SUMMIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Wed Apr 25 00:47:00 CST 2012, time=2012-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900786, encodeId=22861900e8635, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Fri Oct 05 09:47:00 CST 2012, time=2012-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022439, encodeId=1e29202243935, content=<a href='/topic/show?id=53564603527' target=_blank style='color:#2F92EE;'>#实效研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46035, encryptionId=53564603527, topicName=实效研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f2c2500194, createdName=446798725_87912765, createdTime=Sat Aug 18 04:47:00 CST 2012, time=2012-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379429, encodeId=41a113e9429e6, content=<a href='/topic/show?id=4f12504e147' target=_blank style='color:#2F92EE;'>#循证医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50471, encryptionId=4f12504e147, topicName=循证医学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Tue Apr 03 08:47:00 CST 2012, time=2012-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449639, encodeId=9dff1449639c2, content=<a href='/topic/show?id=0bd850468be' target=_blank style='color:#2F92EE;'>#循证#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50468, encryptionId=0bd850468be, topicName=循证)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca95510093, createdName=xjy04, createdTime=Tue Apr 03 08:47:00 CST 2012, time=2012-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561978, encodeId=afc015619e89d, content=<a href='/topic/show?id=309f509e9a' target=_blank style='color:#2F92EE;'>#CORE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5097, encryptionId=309f509e9a, topicName=CORE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Apr 03 08:47:00 CST 2012, time=2012-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605670, encodeId=e4e116056e059, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Apr 03 08:47:00 CST 2012, time=2012-04-03, status=1, ipAttribution=)]
    2012-04-03 docwu2019
  7. [GetPortalCommentsPageByObjectIdResponse(id=1795196, encodeId=5ef21e95196d0, content=<a href='/topic/show?id=aeac1689e5b' target=_blank style='color:#2F92EE;'>#SUMMIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16897, encryptionId=aeac1689e5b, topicName=SUMMIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Wed Apr 25 00:47:00 CST 2012, time=2012-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900786, encodeId=22861900e8635, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Fri Oct 05 09:47:00 CST 2012, time=2012-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022439, encodeId=1e29202243935, content=<a href='/topic/show?id=53564603527' target=_blank style='color:#2F92EE;'>#实效研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46035, encryptionId=53564603527, topicName=实效研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f2c2500194, createdName=446798725_87912765, createdTime=Sat Aug 18 04:47:00 CST 2012, time=2012-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379429, encodeId=41a113e9429e6, content=<a href='/topic/show?id=4f12504e147' target=_blank style='color:#2F92EE;'>#循证医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50471, encryptionId=4f12504e147, topicName=循证医学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Tue Apr 03 08:47:00 CST 2012, time=2012-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449639, encodeId=9dff1449639c2, content=<a href='/topic/show?id=0bd850468be' target=_blank style='color:#2F92EE;'>#循证#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50468, encryptionId=0bd850468be, topicName=循证)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca95510093, createdName=xjy04, createdTime=Tue Apr 03 08:47:00 CST 2012, time=2012-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561978, encodeId=afc015619e89d, content=<a href='/topic/show?id=309f509e9a' target=_blank style='color:#2F92EE;'>#CORE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5097, encryptionId=309f509e9a, topicName=CORE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Apr 03 08:47:00 CST 2012, time=2012-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605670, encodeId=e4e116056e059, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Apr 03 08:47:00 CST 2012, time=2012-04-03, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map